Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from emblem, a phase iib, randomised, double-blind, placebo-controlled, multicentre studyObjective: To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE)....
The mechanistic impact of cd22 engagement with epratuzumab on b cell function: implications for the treatment of systemic lupus erythematosus AbstractEpratuzumab is a B-cell-directed non-depleting monoclonal antibody that targets CD22....
Final results of a phase i radioimmunotherapy trial using 186re-epratuzumab for the treatment of patients with non-hodgkin's lymphoma... The aim of this study was to determine the maximum tolerated dose and a first impression of the therapeutic potential of 186Re-epratuzumab in patients with NHL....
Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in japanese patients with moderate-to-severe systemic lupus erythematosus: results from a phase 1/2 randomized study>Objectives: This 12-week, randomized, double-blind, placebo-controlled, multicenter phase 1/2 study (NCT01449071) assessed the safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus despite standard of care.Methods:...
